All In Biotech

Drug Trial Radar · NCT02224573

An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes

An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.

Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

681

Actual

Start

Jun 11, 2015

Primary completion

Sep 24, 2020

Study completion Sep 24, 2020

Sponsor

Lead sponsor
GW Research LtdJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Aug 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.

Conditions

  • Epilepsy
  • Dravet Syndrome
  • Lennox-Gastaut Syndrome

Interventions

  • GWP42003-PDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment GroupTime frame: up to Week 260
  2. Number of Participants With Clinically Significant Changes in the Indicated Vital Sign Values From the Pre-randomization Baseline of the Core Study at Any Time Post-doseTime frame: up to Week 260
  3. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Body Mass Index (BMI)Time frame: up to Week 260
  4. Number of Participants With Clinically Significant Electrocardiogram (ECG) Values at the Pre-randomization Baseline of the Core Study and at Any Time Post-doseTime frame: up to Week 260
  5. Number of Participants With the Indicated Responses to Questions Regarding Suicidal Ideation and Behavior Using the Children's Columbia-Suicide Severity Rating Scale (C-SSRS) at Day 1 and at Any Time Post-doseTime frame: up to Week 260
  6. Mean Cannabis Withdrawal Scale Score at End of Taper (EOT), the Post-Taper Safety Call, and at Safety Follow-upTime frame: up to Week 260
  7. Mean Pediatric Cannabinoid Withdrawal Scale (PCWS) Score at the End of Treatment, the End of Taper, the Post-Taper Safety Call, and at Safety Follow-upTime frame: up to Week 260
  8. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Red Blood Cells (RBCs) ValuesTime frame: up to Week 260
  9. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hemoglobin LevelsTime frame: up to Week 260
  10. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hematocrit ValuesTime frame: up to Week 260
  11. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular VolumeTime frame: up to Week 260
  12. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular HemoglobinTime frame: up to Week 260
  13. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Platelets, White Blood Cells, Basophils, Eosinophils, Lymphocytes, Monocytes, and NeutrophilsTime frame: up to Week 260
  14. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in the Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils in White Blood Cells (WBCs)Time frame: up to Week 260
  15. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Sodium, Potassium, Blood Urea Nitrogen, Glucose, Calcium, and High-Density Lipoprotein (HDL) CholesterolTime frame: up to week 260
  16. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine (Jaffe), Creatinine (Enzymatic), and BilirubinTime frame: up to Week 260
  17. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine Clearance (Schwartz) and Creatinine Clearance (Cockcroft-Gault)Time frame: up to Week 260
  18. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, and Gamma Glutamyl TransferaseTime frame: up to Week 260
  19. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Albumin and ProteinTime frame: up to Week 260
  20. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in ProlactinTime frame: up to Week 260
  21. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin TimeTime frame: up to Week 260
  22. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin International Normalized RatioTime frame: up to Week 260
  23. Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Insulin-like Growth Factor-1 (IGF-1) LevelsTime frame: up to Week 260
  24. Mean Subject/Caregiver Global Impression of Change (S/CGIC) ScoreTime frame: Baseline; up to Week 260
  25. Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Total Seizure FrequencyTime frame: Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, Week 253 to 264, and Last 12 Weeks
  26. Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Drop Seizure Frequency in Participants With Lennox-Gastaut SyndromeTime frame: Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, and Last 12 Weeks
  27. Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Convulsive Seizure Frequency in Participants With Dravet SyndromeTime frame: Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, Week 253 to 264, and Last 12 Weeks
  28. Number of Participants With Convulsive and Non-convulsive Seizures Greater Than 30 Minutes in Duration (Status Epilepticus)Time frame: Baseline; At last 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.